Commentary

Screening for adolescent substance use; Changing routines during COVID-19


 

The author responds

I thank Dr. Simon for his words of encouragement. I agree that both the S2BI and BSTAD have high sensitivity and specificity and are easy to use for screening for the use of multiple substances. Once substance use is established, both tools recommend administering high-risk assessment with additional scales such as the CRAFFT. During the initial evaluation, many psychiatrists take their patient’s history of substance use in detail, including age of onset, frequency, amount used, severity, and the time of his/her last use, without using a screening instrument. My article focused on instruments that can determine whether there is need for a further detailed evaluation. I agree that the S2BI and BSTAD would assist psychiatrists or physicians in other specialties (eg, pediatrics, family medicine) who might not take a complete substance use history during their initial evaluations.

Shikha Verma, MD
Rogers Behavioral Health
Kenosha, Wisconsin
Assistant Professor
Department of Psychiatry and Behavioral Health
Rosalind Franklin University of Medicine and Science
North Chicago, Illinois

Continue to: Changes as a result of COVID-19

Recommended Reading

COVID-19 prompts ‘lifesaving’ policy change for opioid addiction
Covid ICYMI
New ASAM guideline released amid COVID-19 concerns
Covid ICYMI
Researchers investigate impact of smoking on COVID-19 risk
Covid ICYMI
COVID-19: An opportunity, challenge for addiction treatment, NIDA boss says
Covid ICYMI